Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/18423
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Horsmans, Y. | - |
dc.contributor.author | Colle, I. | - |
dc.contributor.author | Van Vlierberghe, H. | - |
dc.contributor.author | Langlet, P. | - |
dc.contributor.author | Adler, M. | - |
dc.contributor.author | Bourgeois, N. | - |
dc.contributor.author | Brenard, R. | - |
dc.contributor.author | Michielsen, P. | - |
dc.contributor.author | Goossens, A. | - |
dc.contributor.author | BRUCKERS, Liesbeth | - |
dc.date.accessioned | 2015-03-23T15:07:50Z | - |
dc.date.available | 2015-03-23T15:07:50Z | - |
dc.date.issued | 2008 | - |
dc.identifier.citation | ACTA GASTRO-ENTEROLOGICA BELGICA, 71 (3), p. 293-297 | - |
dc.identifier.issn | 0001-5644 | - |
dc.identifier.uri | http://hdl.handle.net/1942/18423 | - |
dc.description.abstract | Background and study aims : The combination of Pegylated (PEG)interferon a-2b and ribavirin is considered to be the standard treatment for naïve chronic hepatitis C patients. Study aims are to evaluate the differences between standard interferon and PEG-interferon by conducting a multi-centre, controlled randomized trial comparing 3 groups. Group A : daily interferon alfa-2b at a dose of 4 MIU + ribavirin, Group B : PEG-interferon alfa-2b at a dose of 100 mcg/week + ribavirin ; Group C : interferon alfa-2b at a dose of 3 MIU TIW + ribavirin Patients and methods : Multicentrer, open label study including naïve chronic Hepatitis C Virus patients randomised in three groups with a ratio of 2:2:1. Group A : daily interferon a-2b (4 MIU s.c. for patients > 65 kg or 0.06 MIU/kg 65 kg or 1.5 μg/kg weekly for patients < 65 kg) and ribavirin and group C (reference arm) : interferon a-2b (3MIU s.c. TWI) and ribavirin. The duration of the treatment was 48 weeks for all 3 groups, with a 6 month follow-up period. 336 patients were enrolled in the study and included in the intention-to-treat analysis ; 78 never started treatment (35 in group A, 28 in group B and 15 in group C) : 101 in group A, 98 in group B and 59 in group C. Results : Demographic data, PCR results and reasons for early withdrawal have been statistically analysed. At baseline, the 3 groups did not show any statistical difference regarding age, gender, race, genotypes and METAVIR score. At week 24 on treatment, HCV ribonucleic acid RNA was undetectable in 87% in group A, in 79% in group B and in 69% in group C. At the end of treatment, 73% 74% and 58% respectively, had a negative PCR result. At week 24 of follow-up, these results were 71%, 64% and 48%, respectively. When comparing the efficacy of the daily interferon (+ ribavirin) and the PEG-interferon (+ ribavirin) regimen, no statistical difference was found (p = 0.32). In group A, 38% of drop-outs were due to adverse events compared to 37% in group B and 58% in group C. No statistical differences were observed regarding safety. Conclusion : Daily weight based interferon a-2b dosing and PEG interferon a-2b weighed based dosing once weekly both in combination with Ribavirin offer the same efficacy and safety rates. (Acta gastro enterol. belg., 2008, 71, 293-297). Key words : chronic hepatitis C, interferon, daily administration, pegylated interferon. | - |
dc.language.iso | en | - |
dc.title | Weekly pegylated interferon alpha-2b vs daily interferon a-2b versus standard regimen of interferon a-2b in the treatment of patients with chronic hepatitis C virus infection | - |
dc.type | Journal Contribution | - |
dc.identifier.epage | 297 | - |
dc.identifier.issue | 3 | - |
dc.identifier.spage | 293 | - |
dc.identifier.volume | 71 | - |
local.bibliographicCitation.jcat | A1 | - |
local.type.refereed | Refereed | - |
local.type.specified | Article | - |
dc.identifier.isi | 000262683500001 | - |
item.fulltext | No Fulltext | - |
item.fullcitation | Horsmans, Y.; Colle, I.; Van Vlierberghe, H.; Langlet, P.; Adler, M.; Bourgeois, N.; Brenard, R.; Michielsen, P.; Goossens, A. & BRUCKERS, Liesbeth (2008) Weekly pegylated interferon alpha-2b vs daily interferon a-2b versus standard regimen of interferon a-2b in the treatment of patients with chronic hepatitis C virus infection. In: ACTA GASTRO-ENTEROLOGICA BELGICA, 71 (3), p. 293-297. | - |
item.contributor | Horsmans, Y. | - |
item.contributor | Colle, I. | - |
item.contributor | Van Vlierberghe, H. | - |
item.contributor | Langlet, P. | - |
item.contributor | Adler, M. | - |
item.contributor | Bourgeois, N. | - |
item.contributor | Brenard, R. | - |
item.contributor | Michielsen, P. | - |
item.contributor | Goossens, A. | - |
item.contributor | BRUCKERS, Liesbeth | - |
item.accessRights | Closed Access | - |
crisitem.journal.issn | 0001-5644 | - |
Appears in Collections: | Research publications |
WEB OF SCIENCETM
Citations
7
checked on May 10, 2024
Page view(s)
36
checked on Nov 7, 2023
Google ScholarTM
Check
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.